ONCOLOGY: February 2009 Volume 23 Number 2 Supplement 1
Infusion Reactions Associated With Monoclonal Antibodies in Patients With Solid Tumors This supplement and associated publication costs were funded by Amgen
Infusion Reactions Associated With Monoclonal Antibodies in Patients With Solid Tumors
This supplement and associated publication costs were funded by Amgen
Infusion reactions are well-known in cancer treatment, occurring with both cytotoxic and biologic agents. The five articles presented in this supplement to ONCOLOGY cover a wide range of topics related to antibody-induced infusion reactions: immunologic mechanisms and risk factors; a focus on anaphylaxis; US and EU perspectives on the state of clinical trials; a health economic analysis of the burden on patients, caregivers, and providers; and a nursing perspective on infusion reaction management.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
